Company intelligence / Profile preview
NovaCell Technology
South Koreanovacelltech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple preclinical candidates, with one atopic dermatitis treatment that received approval for Phase 1 clinical trials in Korea in January 2021.
- Therapeutic areas
- OncologyPulmonologyDermatology
- Modalities
- Peptide-based biotherapeuticsAntibodiesSynthetic peptidesRecombinant polypeptides
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
National Drug Development Project Group (Korea)
Beyond the preview
Go deeper on NovaCell Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovaCell Technology.